We are live on ! Find out more
KTTA icon

Pasithea Therapeutics
KTTA

6 hedge funds and large institutions have $218K invested in Pasithea Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more capital invested

Capital invested by funds: $94.7K → $218K (+$123K)

2.83% more ownership

Funds ownership: 0.06% → 2.89% (+2.8%)

25% less funds holding

Funds holding: 8 → 6 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
+$197K
2
TRCT
Tower Research Capital (TRC)
New York
+$5.15K
3
UBS Group
UBS Group
Switzerland
+$4.32K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$48.8K
2
Northern Trust
Northern Trust
Illinois
-$17.4K
3
Renaissance Technologies
Renaissance Technologies
New York
-$12K
4
Jane Street
Jane Street
New York
-$8.73K

KTTA Hedge Fund Activity: Q1 2024 in Review

6 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2024, worth a combined $218K — up 130% from $94.7K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of KTTA and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $197K. The largest seller was Geode Capital Management, exiting entirely with an estimated $48.8K sold.

  • 6 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2024, down from 8 in Q4 2023.
  • Funds reported $218K of Pasithea Therapeutics stock for Q1 2024, up 130% quarter-over-quarter.
  • 2 funds opened new Pasithea Therapeutics positions in Q1 2024 and 4 closed out, a net change of -2 holders.
  • The largest Pasithea Therapeutics buyer in Q1 2024 was ADAR1 Capital Management, an estimated $197K added.
  • The largest Pasithea Therapeutics seller in Q1 2024 was Geode Capital Management, an estimated $48.8K sold.

Based on aggregated 13F filings for Q1 2024.